Sertindole

CHEMBL12713 Phase 4 Disetujui Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

440.9 g/mol

LogP

4.1

Phase

4

Sertindole is an atypical antipsychotic of the phenylindole class with high affinity for dopamine D2, serotonin 5-HT2A, and alpha-1 adrenergic receptors, used for the treatment of schizophrenia and investigated in bipolar disorder and generalized anxiety disorder. Its unique receptor binding profile, with greater affinity for mesolimbic versus nigrostriatal dopamine pathways, provides antipsychotic efficacy with reduced extrapyramidal side effects. QTc prolongation risk limits its use and requires cardiac monitoring.

Berat Molekul

440,9000 g/mol

LogP

4,10

TPSA

40,50 Å²

Lipinski RO5

Lulus

Area Terapeutik

Schizophrenia Bipolar Disorder Generalized Anxiety Disorder

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1

InChI

InChI=1S/C24H26ClFN4O/c25-18-1-6-23-21(15-18)22(16-30(23)20-4-2-19(26)3-5-20)17-7-10-28(11-8-17)13-14-29-12-9-27-24(29)31/h1-6,15-17H,7-14H2,(H,27,31)

Molecular Formula

C24H26ClFN4O

HBD / HBA

1 / 3

Ikatan yang Dapat Dirotasi

5

Atom Berat

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

Sertindole is an atypical antipsychotic of the phenylindole class with high affinity for dopamine D2, serotonin 5-HT2A, and alpha-1 adrenergic receptors, used for the treatment of schizophrenia and investigated in bipolar disorder and generalized anxiety disorder. Its unique receptor binding profile, with greater affinity for mesolimbic versus nigrostriatal dopamine pathways, provides antipsychotic efficacy with reduced extrapyramidal side effects. QTc prolongation risk limits its use and requires cardiac monitoring.

Yes, Sertindole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL12713. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 60149. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Mencari informasi yang ramah bagi pasien?

Sertindole di PillFYI

Struktur

Data Cepat

Rumus: C24H26ClFN4O

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.